Cargando…
Optimized Therapeutic (177)Lu-Labeled PSMA-Targeted Ligands with Improved Pharmacokinetic Characteristics for Prostate Cancer
Clinical trials have shown the significant efficacy of [(177)Lu]Lu-PSMA-617 for treating prostate cancer. However, the pharmacokinetic characteristics and therapeutic performance of [(177)Lu]Lu-PSMA-617 still need further improvement to meet clinical expectations. The aim of this study was to evalua...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9782218/ https://www.ncbi.nlm.nih.gov/pubmed/36558981 http://dx.doi.org/10.3390/ph15121530 |